Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cyclacel Pharmaceuticals Inc    

 SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 0,77 M
EBIT 2016 -14,1 M
Net income 2016 -11,6 M
Debt 2016 -
Yield 2016 -
Sales 2017 2,00 M
EBIT 2017 -11,9 M
Net income 2017 -9,44 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 21,6x
Capi. / Sales2017 8,33x
Capitalization 16,7 M
More Financials
Company
Cyclacel Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel, mechanism-targeted drugs to treat cancer and other serious disorders.Its lead candidate, sapacitabine, oral nucleoside analogue prodrug that acts through a novel mechanism.It also develops... 
More about the company
Latest news on CYCLACEL PHARMACEUTICALS I
02/23 CYCLACEL PHARMACEUTICALS : CYCC) Tumbles on Failed Tests
02/23 NETWORKNEWSBREAKS – CYCLACEL P : CYCC) Shares Tumble on Disappointing Phas..
02/23 CYCLACEL PHARMACEUTICALS, INC. (NASD : CYCC) Files An 8-K Other Events
02/23 CYCLACEL PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
02/23 Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in El..
02/06 Cyclacel Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Con..
2016 CYCLACEL PHARMACEUTICALS, INC. (NASD : CYCC) Files An 8-K Departure of Directors..
2016 CYCLACEL PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form..
2016 CYCLACEL PHARMACEUTICALS, INC. (NASD : CYCC) Files An 8-K Other Events
2016 CYCLACEL PHARMACEUTICALS, INC. : Other Events (form 8-K)
More news
Sector news : Bio Therapeutic Drugs
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2016 Midday Gainers / Losers
2016 Midday Gainers / Losers
2016 Cyclacel's lead product candidates show encouraging results in early-stage st..
2016 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
2016 Some Ideas For The Next Celator
Advertisement
Chart CYCLACEL PHARMACEUTICALS I
Duration : Period :
Cyclacel Pharmaceuticals I Technical Analysis Chart | US23254L3069 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 7,00 $
Spread / Average Target 79%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Spiro Rombotis President, Chief Executive Officer & Director
David C. U'Prichard Chairman
Paul McBarron COO, CFO, Secretary, Director & Executive VP
David Glover Chief Scientist
John Michael Middlecott Banham Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CYCLACEL PHARMACEUTICA..7.17%17
AMGEN, INC.19.01%128 555
GILEAD SCIENCES, INC.-3.13%92 143
CELGENE CORPORATION3.21%91 979
REGENERON PHARMACEUTIC..-1.67%38 296
ACTELION LTD22.36%28 792
More Results